Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EHOC 2022 | Novel investigational drugs and promising therapies for immune thrombocytopenia

Drew Provan • 30 Sep 2022
EHOC 2022
Immune Thrombocytopenia Non-Malignant Avatrombopag

Drew Provan, BSc, MBChB, MD, FRCP, FRCPath, Queen Mary University of London, London, UK, gives an overview of novel agents being explored for the treatment of immune thrombocytopenia (ITP), including thrombopoietin (TPO) receptor agonists, Bruton’s tyrosine kinase (BTK) inhibitors, and complement inhibitors. This interview took place at the XIII Eurasian Hematology-Oncology Congress (EHOC) held in Istanbul, Turkey.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

Disclosures

Research support: Amgen, Novartis
Honoraria: Amgen, Novartis, SOBI, UCB, argenx
Consultancies: UCB, MedImmune, Ono, SOBI, argenx

More from Drew Provan

1:24
Recent advances in the treatment and management of ITP
Drew Provan • 30 Sep 2022
2:03
Unmet needs in immune thrombocytopenia
Drew Provan • 30 Sep 2022
2:38
The management of ITP during and after the COVID-19 pandemic
Drew Provan • 30 Sep 2022

Related Videos

2:38
Treosulfan vs busulfan conditioning in pediatric patients with non-malignant diseases
Rita Beier • 15 Apr 2024
2:18
A global view of transfusion-dependent thalassemia: standard of care, outcomes, and unmet needs
Ali Taher • 15 Apr 2024
1:24
The future of CAR T-reg cells: organ transplantation & autoimmune disease
Zinaida Good • 9 Apr 2024
1:23
Developing a PRO collection tool for patients with SCD: key themes which are important to patients
Nirmish Shah • 8 Dec 2023
The content of VJHemOnc is intended for healthcare professionals